Clinical Characteristics and Mortality of Patients Screened for Entry Into the Trandolapril Cardiac Evaluation (TRACE) Study
Section snippets
Methods
Patients: Details of the Trandolapril Cardiac Evaluation (TRACE) protocol have been published elsewhere.6 TRACE is a randomized, placebo-controlled, double-blind, parallel-group trial of the ACE inhibitor trandolapril among patients with LV systolic dysfunction shortly after an AMI. The primary end point of the trial is all-cause mortality.
In brief, consecutive patients with an enzyme confirmed AMI in 27 Danish hospitals were screened. An echocardiography and a medical history were obtained. LV
Results
A total of 7,001 enzyme-confirmed myocardial infarctions were screened for entry into the study at the 27 participating centers. The 7,001 infarctions represented 6,676 patients: 272 patients were screened twice, 19 three times, and 5 four times. Descriptive statistics of the 7,001 infarctions are listed in Table II. In this table, the numbers refer to infarctions, not patients. However, if descriptive statistics are calculated corresponding to initial infarction, the result is nearly the same:
Discussion
The 1-year mortality of patients with AMI screened for entry into TRACE and of those finally randomized were very similar, 23% and 24%. With regard to other studies attempting to randomize high-risk patients, a question is raised as to the possibility of extrapolating the result of the trial beyond those randomized.
The 7,001 AMIs screened for entry into TRACE were representative of the general population with AMI admitted alive to the hospital when 1-year mortality results are compared with
Acknowledgment
We thank Laurent Auclair, MD, and David Cole, PhD, for their helpful comments.
References (10)
- et al.
Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction
Am J Cardiol
(1990) - et al.
Applying results of randomized trials to clinical practice: impact of losses before randomization
Br Med J
(1984) - et al.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial
N Engl J Med
(1992) The effect of ramipril on mortality and morbidity of survival of acute myocardial infarction with clinical evidence of heart failure
Lancet
(1993)- et al.
Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis
Br Med J
(1993)
Cited by (75)
Unreported exclusion and sampling bias in interpretation of randomized controlled trials in patients with STEMI
2019, International Journal of CardiologyRenin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
2016, Progress in Cardiovascular DiseasesCitation Excerpt :These different modes of RAAS inhibition may explain some of the clinical differences between ACEIs, ARBs and DRIs. The evidence for ACEIs and reduced CV outcomes largely stem from the placebo-controlled trials of heart failure (HF)10 and post-MI.11 Beneficial effect of ACEIs was also seen in the placebo-controlled HOPE4 trial which included high-risk patients who had evidence of vascular disease or diabetes plus one other CV risk factor and who were not known to have HF.
Maximizing scientific knowledge from randomized clinical trials
2010, American Heart JournalCitation Excerpt :The screening database provided unique insight into the presentation and prognosis of patients with acute myocardial infarction. More than 40 papers have been published based on the TRACE registry.15 The advantage of trial screening registries over trial databases is the fact that they are broader and more representative of the disease entity.
Hypertension and Cardiac Failure in its Various Forms
2009, Medical Clinics of North America
The Trandolapril Cardiac Evaluation study was sponsored by Roussel UCLAF, Romainville, France, and Knoll AG, Ludwigshafen, Germany